Nimotuzumab
- Generic Name
- Nimotuzumab
- Drug Type
- Biotech
- CAS Number
- 780758-10-3
- Unique Ingredient Identifier
- 6NS400BXKH
- Indication
Investigated for use/treatment in head and neck cancer, brain cancer, pediatric indications, pancreatic cancer, lung cancer, and colorectal cancer.
- Associated Conditions
- Advanced Head and Neck Cancer, Advanced Stage Head and Neck Cancer, Glioblastoma Multiforme (GBM), High Grade Glioma (HGG), Advanced Epithelial Tumor of the Head and Neck
Study of Nimotuzumab and Cisplatin/Radiotherapy for Locally Advanced Head and Neck Squamous Cell Cancer
Phase 2
Completed
- Conditions
- Head and Neck Cancer
- Interventions
- First Posted Date
- 2008-06-20
- Last Posted Date
- 2023-02-28
- Lead Sponsor
- National Cancer Centre, Singapore
- Target Recruit Count
- 32
- Registration Number
- NCT00702481
- Locations
- 🇸🇬
National Cancer Center Singapore, Singapore, Singapore
Nimotuzumab in Children With Intrinsic Pontine Glioma
Completed
- Conditions
- Diffuse Instrinsic Ponitine Glioma
- First Posted Date
- 2007-11-21
- Last Posted Date
- 2013-03-29
- Lead Sponsor
- Oncoscience AG
- Target Recruit Count
- 41
- Registration Number
- NCT00561691
- Locations
- 🇩🇪
University Bonn, Children's Medical Hospital, Bonn, Germany
Nimotuzumab in Adults With Pancreatic Cancer
- First Posted Date
- 2007-11-21
- Last Posted Date
- 2015-10-15
- Lead Sponsor
- Oncoscience AG
- Target Recruit Count
- 188
- Registration Number
- NCT00561990
- Locations
- 🇩🇪
Marienhospital Herne, Herne, Germany
Study of Nimotuzumab and Irinotecan in Metastatic Colorectal Cancer
Phase 2
Terminated
- Conditions
- Colorectal Cancer
- Interventions
- First Posted Date
- 2007-06-28
- Last Posted Date
- 2008-11-17
- Lead Sponsor
- YM BioSciences
- Target Recruit Count
- 100
- Registration Number
- NCT00493857
- Locations
- 🇨🇦
Tom Baker Cancer Center, Calgary, Alberta, Canada
🇨🇦Dr. H. Bliss Purphy Cancer Centre, St. John's, Newfoundland and Labrador, Canada
🇨🇦Royal Victoria Hospital, Barrie, Ontario, Canada
Phase I Study of Nimotuzumab in Solid Tumours
Phase 1
Completed
- Conditions
- Advanced and/or Metastatic Solid Tumours
- First Posted Date
- 2006-08-29
- Last Posted Date
- 2007-02-28
- Lead Sponsor
- YM BioSciences
- Target Recruit Count
- 18
- Registration Number
- NCT00369252
- Locations
- 🇨🇦
Princess Margaret Hospital, Toronto, Ontario, Canada
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath